INNOVENTRIC

Innoventric is a New York City-based medical technology company founded in 2017, specializing in transcatheter treatments for tricuspid regurgitation (TR). The company is recognized for its leadership in cross-caval technologies, developing advanced devices to enhance treatment options for patients with this complex heart condition. Innoventric is committed to improving patient care through data-driven approaches and clinical research. The company's product portfolio includes innovative devices such as Trillium™, a pioneering cross-caval device that has shown significant hemodynamic improvements, and Koala™, a docking station for valve placement. Unica™ is another device designed for patients with smaller anatomies, facilitating future procedures. Innoventric's minimally invasive solutions aim to reduce procedure times and improve outcomes for a wide range of patients, including those typically considered ineligible for treatment. Innoventric collaborates with hospitals and specialized cardiac centers, attracting significant investment to support its mission. The company is backed by a team of experts in cardiac signal analytics and medical device innovation, ensuring a strong foundation for its continued growth and impact in the field of structural heart disease.

• Employees 22
• Founded 2017
• Total Funding $42500000